TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NVO

NVO

NOVO NORDISK A S

Next earnings Aug 5, 2026 · consensus $5.28 EPS, $73.1B rev

Sell
$50.43
▲ +4.32%
$50.43▼ -22.83%
over 1Y
L $34.77H $68.39
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.3%
1W+5.9%
1M+17.5%
3M+36.4%
YTD-0.2%
1Y-22.8%
OverviewValuationQualityFilings
Rating
Sell
Quality
C
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 37 analysts
Hold

Mixed signals in the latest filings.

NOVO NORDISK A S shows limited reported revenue.

On these fundamentals, the SEC-figure screen rates NVO a SELL.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 3:08 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Key statistics

Valuation

Enterprise value$223B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-222026-06-24open ↗SCHEDULE 13G/AFiling2026-06-22open ↗11-KPeriod ending 2025-12-312026-06-22open ↗11-KPeriod ending 2025-12-312026-06-22open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-082026-06-08open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-262026-05-27open ↗6-KPeriod ending 2026-05-222026-05-22open ↗SDFiling2026-05-22open ↗6-KPeriod ending 2026-05-222026-05-22open ↗

Quality score

C
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumC
34.7752-week68.39
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is NOVO NORDISK A S (NVO) a buy?
NVO currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is NOVO NORDISK A S's quality score?
NVO scores 56.931784711196045/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000353278, latest 6-K filed 2026-06-29) · EODHD · as of 6/18/2026, 7:08:03 AM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Dividends

Semi-annual
Yield (TTM)
3.7%
Annual / share
$1.86
Last ex-date
2026-03-30
Last amount
$1.28
ex 2026-03-30paid 2026-04-08$1.28
ex 2025-08-18paid 2025-08-26$0.58
ex 2025-03-31paid 2025-04-08$1.10
ex 2024-08-16paid 2024-08-26$0.51
ex 2024-03-22paid 2024-04-02$0.93
ex 2023-08-18paid 2023-08-29$0.44

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-10-22Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-10-20Marjorie Taylor GreeneBuy$1.00K–$15.0KPTR ↗
2025-09-12Valerie HoyleBuy$1.00K–$15.0KPTR ↗
2025-09-12Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-29Marjorie Taylor GreeneBuy$1.00K–$15.0KPTR ↗
2025-08-20Marjorie Taylor GreeneBuy$15.0K–$50.0KPTR ↗
2025-08-14Scott Scott FranklinBuy$15.0K–$50.0KPTR ↗
2025-08-14Scott Scott FranklinBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?Bullish
nasdaq.com· 2026-07-04
Novo Nordisk (NVO) Stock May Be 48% Undervalued On Medicare GLP 1 CoverageBullish
finance.yahoo.com· 2026-07-03
Here's Why Viking Therapeutics Stock Surged Higher in JuneBullish
nasdaq.com· 2026-07-03
Here's Why Viking Therapeutics Stock Surged Higher in JuneBullish
finance.yahoo.com· 2026-07-03
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 InclusionBullish
finance.yahoo.com· 2026-07-03
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?Bullish
finance.yahoo.com· 2026-07-03

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score57 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 60d
Bullish
+0.07
vs typical · 465 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.